Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 6/20 | 0.69 |
| ▸ | F9 | P00740 | 9/20 | 0.69 |
| ▸ | PLAU | P00749 | 6/20 | 0.55 |
| ▸ | F10 | P00742 | 5/20 | 0.53 |
| ▸ | C1S | P09871 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712431 | 0.88 | F9 (0.71) | SLC9A1F9PLAUF10 | |
| Hydrochloric Acid SCHEMBL9432601 | 0.87 | F9 (0.69) | SLC9A1F9PLAUF10 | |
| SCHEMBL13709464 | 0.82 | F9 (1.00) | SLC9A1F9PLAUF10 | |
| SCHEMBL825912 | 0.82 | SLC9A1 (1.00) | SLC9A1 | |
| SCHEMBL829351 | 0.82 | SLC9A1 (0.69) | SLC9A1F9 | |
| SCHEMBL829573 | 0.81 | SLC9A1 (0.71) | SLC9A1F9PLAUF10 | |
| Hydrochloric Acid SCHEMBL9431772 | 0.81 | F9 (0.97) | SLC9A1F9PLAUF10 | |
| SCHEMBL13712494 | 0.80 | F9 (0.74) | SLC9A1F9PLAUF10 | |
| SCHEMBL27715656 | 0.79 | SLC9A1 (0.62) | SLC9A1F9PLAUF10 | |
| SCHEMBL13712427 | 0.79 | F9 (0.64) | SLC9A1F9PLAUF10C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | F12, F5, F3 | SLC9A1 1287/4885F9 5/4885PLAU 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.